Clinical Scorecard: Targeting bone marrow pathway may curb bone loss

At a Glance

Key Highlights

• STING signaling in bone marrow macrophages increased with age in the mouse models.
• Myeloid-specific STING deletion was associated with lower bone mass in early adulthood but attenuated bone loss from 10 to 24 months; the higher bone mass at 24 months was not statistically significant.
• Macrophage-targeted STING knockdown from 12 to 18 months improved several bone microarchitecture measures and was associated with enhanced bone formation and reduced marrow adipocyte accumulation.
• Combined H-151 and NMN treatment improved bone microarchitecture measures in mice; the study did not include separate treatment groups to determine each agent’s contribution.
• Macrophage-targeted CD38 knockdown attenuated bone loss and improved mesenchymal stem cell mitochondrial function and osteogenic differentiation.

Guideline-Based Recommendations

Diagnosis

• The study evaluated bone mineral density and trabecular bone measures using microcomputed tomography in mice.
• No human diagnostic criteria or recommendations were reported.

Management

• STING inhibition, combined H-151 and NMN treatment, and macrophage-targeted CD38 knockdown were investigated in mice; the findings do not establish human treatment recommendations.
• The authors reported that bone microarchitecture improvements with H-151 plus NMN were comparable to those observed with alendronate sodium in the mouse experiment.

Monitoring & Follow-up

• Study outcomes included bone mineral density, trabecular bone volume fraction, number, thickness and separation, bone formation, marrow adipocyte accumulation, inflammatory signaling, mitochondrial function, and NAD-positive metabolism.
• No clinical monitoring recommendations for people were reported.

Risks

• The findings are from preclinical models and do not establish efficacy or safety in humans.
• Myeloid-specific STING deletion also affected other myeloid cells, including osteoclast precursors, so their contributions could not be excluded.
• The marrow adipocyte-targeting approach could also affect stromal and adipogenic progenitor cells.
• The combined H-151 and NMN experiment lacked individual treatment groups, limiting assessment of each intervention’s separate contribution.

Patient & Prescribing Data

No human patients were studied. Experiments used male mice aged 3 to 24 months.

In mice, interventions included macrophage-targeted STING knockdown, H-151 plus NMN, and macrophage-targeted CD38 knockdown. The study provides no human dosing, prescribing, efficacy, or safety data.

Clinical Best Practices

• Interpret the reported interventions as preclinical findings; the study does not support prescribing them to people.
• Consider the study’s stated limitations when interpreting pathway-specific effects, including effects on other myeloid and progenitor cells and the absence of separate H-151 and NMN treatment groups.

Related Resources & Content

• Advanced Science (study source; article title and URL not provided)